



## **Cyclacel Pharmaceuticals To Present At Rodman And Renshaw 3rd Annual Global Healthcare Conference**

**SHORT HILLS, NJ, MAY 4, 2006** – Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced today that Spiro Rombotis, President and Chief Executive Officer, will present an overview of the Company and its pipeline at the Rodman and Renshaw 3rd Annual Global Healthcare Conference in Monte Carlo, Monaco. Cyclacel, which began trading on the Nasdaq National Market on March 28 and recently raised \$45.3 million in a private placement, is focused on the discovery and development of small molecule cell cycle inhibitors for the treatment of cancer and other serious diseases. The Company's pipeline includes seliciclib (CYC202) and sapacitabine (CYC682), in clinical trials for the treatment of cancer, an aurora kinase inhibitor (CYC116) in late preclinical development, a large portfolio of development candidates, and a productive drug discovery engine. Mr. Rombotis' presentation will take place on Monday, May 15, 2006 at 8:40 am Central European Summer Time in the Atlantique Salon – Western, located on the second floor of Le Meridien Beach Plaza Hotel, 22 Avenue Princesse Grace, Monte Carlo, Monaco.

The presentation will be webcast live at: <http://wsw.com/webcast/rsshq8/cycc>. The webcast presentation will be available for 90 days.

### **About Cyclacel Pharmaceuticals, Inc.**

Cyclacel is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. The Company is currently evaluating seliciclib (CYC202), an orally-available cyclin dependent kinase inhibitor, in Phase II clinical trials for the treatment of lung cancer. Sapacitabine (CYC682) is an orally-available, cell cycle modulating nucleoside analog in Phase I clinical trials for the treatment of cancer. CYC116 is an orally-available, Aurora kinase inhibitor in IND-directed preclinical development. Several additional programs are at an earlier stage.

Note: The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.

### **Risk Factors**

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risk that Cyclacel will not obtain approval to market its products, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. These factors and others are more fully discussed under "Risk Factors" in the registration statement on Form S-4 (File No. 333-131225) and in the other reports of Cyclacel filed with the SEC.

### **Contacts for Cyclacel:**

For Investors:  
TS Communications Group, LLC (914) 921-5900  
Tara Spiess

For Media:  
Feinstein Kean Healthcare (617) 577-8110  
Kate Weiss